Los Angeles Capital Management’s Travere Therapeutics TVTX Stock Holding History

Los Angeles Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$749K	Buy	25,218 +5,890	+30%	+$176K	﹤0.01%	756
2025 Q4	$573K	Buy	19,328 +2,825	+17%	+$91.9K	﹤0.01%	837
2025 Q3	$394K	Buy	+16,503	New	+$310K	﹤0.01%	1018
2025 Q1	–	Sell	-15,996	Closed	-$279K	–	1230
2024 Q4	$279K	Sell	15,996 -11,955	-43%	-$211K	﹤0.01%	954
2024 Q3	$391K	Sell	27,951 -56,866	-67%	-$592K	﹤0.01%	931
2024 Q2	$697K	Sell	84,817 -8,600	-9%	-$57.9K	﹤0.01%	765
2024 Q1	$720K	Buy	+93,417	New	+$788K	﹤0.01%	781
2017 Q4	–	Sell	-14,010	Closed	-$349K	–	1388
2017 Q3	$349K	Buy	+14,010	New	+$308K	﹤0.01%	1113

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Los Angeles Capital Management's TVTX Position: Q1 2026 in Review

Los Angeles Capital Management increased its Travere Therapeutics (TVTX) stake by 30% in Q1 2026, buying an estimated $176K and bringing the position to 25,218 shares worth $749K. The position accounts for ﹤0.01% of the portfolio, ranked #756.

Los Angeles Capital Management first reported a position in TVTX in Q3 2017 and has held it in 8 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Los Angeles Capital Management held 25,218 shares of Travere Therapeutics worth $749K as of Q1 2026.
Los Angeles Capital Management bought 5,890 Travere Therapeutics shares in Q1 2026, an estimated $176K.
Travere Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #756 holding.
Los Angeles Capital Management first reported a position in Travere Therapeutics in Q3 2017 and has held it in 8 quarters since.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.